Powered by

Stemline Therapeutics Announces that CMS Grants New Technology Add-on Payment (NTAP) to ELZONRISĀ®

Aug 06, 2019 - GlobeNewswire

NEW YORK, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that the Centers for Medicare & Medicaid Services (CMS) granted approval for a new technology add-on payment (NTAP) for ELZONRIS for the treatment of adult and pediatric patients, two years and older, with blastic plasmacytoid dendritic cell neoplasm (BPDCN).